Pfizer filed a lawsuit aimed at blocking Novo Nordisk's acquisition of the obesity drug company Metsera

Wallstreetcn
2025.10.31 22:32

Pfizer has sued Metsera Inc. and Novo Nordisk AS, seeking to block Novo Nordisk's competitive acquisition of this emerging obesity drug company. Pfizer is requesting the Delaware Chancery Court to prevent Metsera from completing the transaction with Novo Nordisk, allowing Pfizer time to obtain a hearing. Pfizer stated that under the merger agreement, Novo Nordisk's offer does not meet the criteria for a "Superior Company Proposal." Pfizer announced that U.S. antitrust enforcement agencies have approved its continued pursuit of the acquisition offer for Metsera, stating that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has ended, "satisfying the regulatory review requirements for the proposed acquisition."

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.